Jason T. Olin, PhD
Affiliations: | 1987-1992 | Psychology | University of Southern California, Los Angeles, CA, United States |
| 1992-2000 | Psychiatry | USC Keck School of Medicine, Los Angeles, CA, United States | |
| 2000-2003 | DSIR | National Institute of Mental Health (NIMH) | |
| 2019-2022 | Medical Affairs | Akebia Therapeutics | |
| 2022- | Private Practice, Los Angeles, United States |
Website:
http://www.jasonlinphd.comGoogle:
"Jason Olin"Mean distance: 19.36
Parents
Sign in to add mentor| Elizabeth Madeline Zelinski | grad student | 1987-1992 | USC |
| Lon S. Schneider | post-doc | USC |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Farlow MR, Grossberg GT, Meng X, et al. (2011) Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry. 26: 1236-43 |
| Alva G, Grossberg GT, Schmitt FA, et al. (2011) Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry. 26: 356-63 |
| Grossberg GT, Olin JT, Somogyi M, et al. (2011) Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. International Journal of Clinical Practice. 65: 465-71 |
| Grossberg G, Meng X, Olin JT. (2011) Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 26: 65-71 |
| Sadowsky CH, Dengiz A, Meng X, et al. (2010) Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Primary Care Companion to the Journal of Clinical Psychiatry. 12 |
| Grossberg GT, Schmitt FA, Xiangyi Meng, et al. (2010) Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease American Journal of Alzheimer's Disease and Other Dementias. 25: 627-633 |
| Schmitt FA, Farlow MR, Meng X, et al. (2010) Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. Cns Neuroscience & Therapeutics. 16: 330-6 |
| Farlow MR, Grossberg G, Gauthier S, et al. (2010) The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion. 26: 2441-7 |
| Olin JT, Aarsland D, Meng X. (2010) Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dementia and Geriatric Cognitive Disorders. 29: 510-5 |
| Cummings JL, Ferris SH, Farlow MR, et al. (2010) Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders. 29: 406-12 |